삼천당제약

000250KOSDAQ

48.1 / 100

Reference Date: 2026-09-08

Financial Score15.0 / 40

News Sentiment18.1 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Slightly down 1.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Samcheon Pharmaceutical, established in 1943, is a leading manufacturer and distributor of prescription pharmaceuticals, specializing in antibiotics, cardiovascular treatments, digestive system medications, and ophthalmic solutions. In 2024, its consolidated sales reached 231.8 billion won, a 9.9% increase from the previous year, with its subsidiary Optus Pharmaceuticals reporting a 6.4% rise in sales to 87.16 billion won.

Number of Employees

436people

Average Salary

65.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

721.24Industry Average 15.000.0Point

48.1x industry avg (risky)

PBR

10.52Industry Average 1.200.0Point

8.8x industry avg (risky)

ROE

3.37Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

25.05Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲9.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲74.1% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 0.1% (improving, 3yr)

Detailed News Sentiment

12 totalPositive 5Neutral 2Negative 5Average Sentiment Score 72.5

Negative
"월요일 혹시나 했더니" 속수무책…대장주 '흔들'에 코스닥 낙폭↓
코스닥 제약바이오 섹터의 약세로 인해 삼천당제약을 포함한 코스닥 지수가 추가 하락을 겪고 있다.
Negative
경쟁사 다 밝히는데…삼천당 아일리아 출시 시점 비공개 '왜'
삼천당제약의 아일리아 바이오시밀러 출시 시점 미공개로 인해 투자자들의 불안감이 증가하고 있다.
Negative
삼천당제약 주가 급락에…전인석 증여세 마련 차질
삼천당제약의 주가 급락으로 인해 오너 일가의 증여세 납부 부담이 증가하여 자금 조달 계획에 어려움이 예상되며, 이는 주가 하락과 지배구조에 부정적 영향을 미칠 것으로 보인다.

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 163,000Won52-week high 1,184,00052-week low 126,500

1-month return3.0Point

1m -1.03% (flat)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral반기보고서 (2026.06)2026-08-14
Neutral주식등의대량보유상황보고서(일반)2026-08-14